We are live on ! Find out more
AVEO

AVEO Pharmaceuticals, Inc.
AVEO

Delisted

AVEO was delisted on the 19th of January, 2023.

Back to rankings

61 hedge funds and large institutions have $26.5M invested in AVEO Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $2.42M | Put options by funds: $1.29M

25% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 12

3% more funds holding

Funds holding: 59 → 61 (+2)

14% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 14

27% less capital invested

Capital invested by funds: $36.2M → $26.5M (-$9.62M)

Holders
61
Holders Change
+2
Holders Change %
+3.39%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
15
Increased
12
Reduced
14
Closed
12
Calls
$2.42M
Puts
$1.29M
Net Calls
+$1.12M
Net Calls Change
+$20K

Top Buyers

Rank Fund Capital Flow
1
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$1.07M
2
GCP
GSA Capital Partners
United Kingdom
+$506K
3
BlackRock
BlackRock
New York
+$239K
4
Marshall Wace
Marshall Wace
United Kingdom
+$217K
5
Two Sigma Investments
Two Sigma Investments
New York
+$75.5K

Top Sellers

Rank Fund Capital Flow
1
6CM
683 Capital Management
New York
-$1.67M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$523K
3
Millennium Management
Millennium Management
New York
-$159K
4
Geode Capital Management
Geode Capital Management
Massachusetts
-$119K
5
Baird Financial Group
Baird Financial Group
Wisconsin
-$83K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
26
Goldman Sachs
New York
$28K -$24.2K -3,290 -42%
SIM
27
Spark Investment Management
New York
$23K +$27.2K +3,700 New
RJA
28
Raymond James & Associates
Florida
$21K -$736 -100 -3%
California Public Employees Retirement System
29
California Public Employees Retirement System
California
$21K – – –
UBS Group
30
UBS Group
Switzerland
$21K +$10.9K +1,476 +80%
D.E. Shaw & Co
31
D.E. Shaw & Co
New York
$20K +$23K +3,128 New
Charles Schwab
32
Charles Schwab
California
$18K – – –
SXL
33
Summit X LLC
Missouri
$18K +$6.11K +830 +40%
AFP
34
Ausdal Financial Partners
Iowa
$17K – – –
CIBC Private Wealth Group
35
CIBC Private Wealth Group
Georgia
$17K +$3.68K +500 +23%
LFG
36
Larson Financial Group
Missouri
$15K -$1.47K -200 -8%
GC
37
Grimes & Company
Massachusetts
$14K – – –
Citigroup
38
Citigroup
New York
$12K -$9.13K -1,240 -41%
CC
39
Cannell & Co
New York
$12K – – –
WS
40
Wedbush Securities
California
$12K +$14.7K +2,000 New
ECM
41
ExodusPoint Capital Management
New York
$11K +$13K +1,770 New
Bank of America
42
Bank of America
North Carolina
$10K – – –
TFS
43
TrustCore Financial Services
Tennessee
$10K – – –
Janney Montgomery Scott
44
Janney Montgomery Scott
Pennsylvania
$7K -$3.02K -410 -27%
LPL Financial
45
LPL Financial
California
$7K +$7.84K +1,065 New
BBI
46
Baxter Bros Inc
Connecticut
$7K +$8.1K +1,100 New
Commonwealth Equity Services
47
Commonwealth Equity Services
Massachusetts
$6K – – –
EWM
48
Edge Wealth Management
New York
$6K – – –
SC
49
Scotia Capital
Ontario, Canada
$6K – – –
Royal Bank of Canada
50
Royal Bank of Canada
Ontario, Canada
$5K – – –
1
2
3

AVEO Hedge Fund Activity: Q4 2019 in Review

61 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in AVEO Pharmaceuticals, Inc. (AVEO) for Q4 2019, worth a combined $26.5M — down 27% from $36.2M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new AVEO positions and 12 closed out — a net gain of 3 holders — while 12 added to existing stakes and 14 trimmed.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $1.07M. The largest seller was 683 Capital Management, exiting entirely with an estimated $1.67M sold.

  • 61 institutional investors held AVEO Pharmaceuticals, Inc. (AVEO) as of Q4 2019, up from 59 in Q3 2019.
  • Funds reported $26.5M of AVEO Pharmaceuticals, Inc. stock for Q4 2019, down 27% quarter-over-quarter.
  • 15 funds opened new AVEO Pharmaceuticals, Inc. positions in Q4 2019 and 12 closed out, a net change of +3 holders.
  • The largest AVEO Pharmaceuticals, Inc. buyer in Q4 2019 was Jacobs Levy Equity Management, an estimated $1.07M added.
  • The largest AVEO Pharmaceuticals, Inc. seller in Q4 2019 was 683 Capital Management, an estimated $1.67M sold.

Based on aggregated 13F filings for Q4 2019.